Want to see HK:2500 full AI Analyst Report?
Venus Medtech (Hangzhou), Inc. Class H (2500) Ratios
Venus Medtech (Hangzhou), Inc. Class H Ratios
HK:2500's free cash flow for Q2 2026 was $-167.31M. For the 2026 fiscal year, HK:2500's free cash flow was decreased by $-3.45M and operating cash flow was $-163.86M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.77 | 2.22 | 2.00 | 5.02 | 16.49 |
| Quick Ratio | 2.37 | 1.95 | 1.86 | 4.81 | 16.06 |
| Cash Ratio | 0.73 | 0.82 | 0.96 | 3.82 | 14.17 |
| Solvency Ratio | -0.41 | -0.58 | -0.39 | -0.57 | -0.67 |
| Operating Cash Flow Ratio | -1.34 | 0.07 | -0.76 | -1.48 | -2.19 |
| Short-Term Operating Cash Flow Coverage | -64.22 | 1.36 | -1.33 | -3.28 | -93.25 |
| Net Current Asset Value | $ -89.86M | $ -236.19M | $ 113.70M | $ 817.45M | $ 2.96B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.09 | 0.11 | 0.19 | 0.17 | 0.01 |
| Debt-to-Equity Ratio | 0.12 | 0.17 | 0.28 | 0.25 | 0.02 |
| Debt-to-Capital Ratio | 0.11 | 0.14 | 0.22 | 0.20 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.08 | 0.11 | 0.08 | 0.14 | 0.00 |
| Financial Leverage Ratio | 1.43 | 1.47 | 1.51 | 1.46 | 1.12 |
| Debt Service Coverage Ratio | -10.99 | -17.26 | -1.04 | -3.61 | -46.71 |
| Interest Coverage Ratio | -19.39 | -20.82 | -9.41 | -14.57 | -146.27 |
| Debt to Market Cap | 0.17 | 0.12 | 0.32 | 0.14 | 0.00 |
| Interest Debt Per Share | 0.53 | 0.88 | 2.03 | 2.16 | 0.17 |
| Net Debt to EBITDA | -0.17 | -0.12 | -0.09 | 0.98 | 8.90 |
| Profitability Margins | |||||
| Gross Profit Margin | 69.05% | 78.11% | 79.21% | 77.25% | 77.99% |
| EBIT Margin | -112.56% | -153.78% | -136.89% | -273.51% | -90.33% |
| EBITDA Margin | -80.83% | -130.19% | -111.49% | -245.87% | -77.92% |
| Operating Profit Margin | -112.56% | -73.61% | -120.07% | -159.97% | -67.00% |
| Pretax Profit Margin | -131.98% | -157.32% | -149.65% | -284.49% | -90.79% |
| Net Profit Margin | -132.89% | -151.71% | -143.22% | -260.22% | -89.85% |
| Continuous Operations Profit Margin | -132.89% | -152.36% | -148.37% | -276.05% | -89.31% |
| Net Income Per EBT | 100.69% | 96.44% | 95.70% | 91.47% | 98.96% |
| EBT Per EBIT | 117.25% | 213.71% | 124.64% | 177.84% | 135.50% |
| Return on Assets (ROA) | -16.17% | -21.98% | -15.94% | -20.02% | -7.31% |
| Return on Equity (ROE) | -23.12% | -32.31% | -24.10% | -29.32% | -8.22% |
| Return on Capital Employed (ROCE) | -15.15% | -12.00% | -16.35% | -13.57% | -5.69% |
| Return on Invested Capital (ROIC) | -14.88% | -11.40% | -14.26% | -12.53% | -5.57% |
| Return on Tangible Assets | -36.74% | -40.43% | -24.79% | -30.82% | -8.72% |
| Earnings Yield | -43.55% | -30.90% | -31.56% | -19.18% | -3.53% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.46 | 1.42 | 1.69 | 1.34 | 1.38 |
| Payables Turnover | 5.95 | 3.41 | 3.02 | 10.13 | 10.46 |
| Inventory Turnover | 0.98 | 1.05 | 0.90 | 0.89 | 1.01 |
| Fixed Asset Turnover | 2.64 | 0.90 | 0.71 | 0.86 | 1.59 |
| Asset Turnover | 0.12 | 0.14 | 0.11 | 0.08 | 0.08 |
| Working Capital Turnover Ratio | 0.71 | 0.76 | 0.35 | 0.16 | 0.13 |
| Cash Conversion Cycle | 560.91 | 496.86 | 498.41 | 648.52 | 591.26 |
| Days of Sales Outstanding | 250.20 | 256.69 | 215.87 | 272.44 | 265.15 |
| Days of Inventory Outstanding | 372.05 | 347.20 | 403.49 | 412.11 | 361.02 |
| Days of Payables Outstanding | 61.34 | 107.03 | 120.95 | 36.03 | 34.90 |
| Operating Cycle | 622.25 | 603.89 | 619.36 | 684.55 | 626.16 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.73 | 0.05 | -1.39 | -1.67 | -1.04 |
| Free Cash Flow Per Share | -0.76 | -0.04 | -1.99 | -2.07 | -1.37 |
| Dividend Paid and CapEx Coverage Ratio | -29.84 | 0.57 | -2.32 | -4.08 | -3.15 |
| Capital Expenditure Coverage Ratio | -29.84 | 0.57 | -2.32 | -4.08 | -3.15 |
| Operating Cash Flow Coverage Ratio | -1.48 | 0.06 | -0.74 | -0.81 | -6.46 |
| Operating Cash Flow to Sales Ratio | -1.05 | 0.05 | -1.24 | -1.79 | -1.10 |
| Free Cash Flow Yield | -35.48% | -0.77% | -39.15% | -16.47% | -5.69% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.30 | -3.24 | -3.17 | -5.21 | -28.30 |
| Price-to-Sales (P/S) Ratio | 3.05 | 4.91 | 4.54 | 13.57 | 25.42 |
| Price-to-Book (P/B) Ratio | 0.53 | 1.05 | 0.76 | 1.53 | 2.33 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.82 | -129.73 | -2.55 | -6.07 | -17.56 |
| Price-to-Operating Cash Flow Ratio | -2.91 | 97.37 | -3.66 | -7.56 | -23.14 |
| Price-to-Earnings Growth (PEG) Ratio | 0.05 | -2.60 | 0.09 | -0.03 | -0.30 |
| Enterprise Value Multiple | -3.94 | -3.89 | -4.16 | -4.54 | -23.73 |
| Enterprise Value | 977.49M | 2.38B | 2.28B | 4.53B | 7.69B |
| EV to EBITDA | -3.94 | -3.89 | -4.16 | -4.54 | -23.73 |
| EV to Sales | 3.19 | 5.06 | 4.64 | 11.15 | 18.49 |
| EV to Free Cash Flow | -2.94 | -133.72 | -2.61 | -4.99 | -12.77 |
| EV to Operating Cash Flow | -3.04 | 100.36 | -3.74 | -6.22 | -16.83 |
| Tangible Book Value Per Share | 0.80 | 1.66 | 3.07 | 4.07 | 8.68 |
| Shareholders’ Equity Per Share | 4.03 | 5.05 | 6.67 | 8.24 | 10.36 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | 0.03 | 0.01 | 0.03 | 0.02 |
| Revenue Per Share | 0.70 | 1.08 | 1.12 | 0.93 | 0.95 |
| Net Income Per Share | -0.93 | -1.63 | -1.61 | -2.42 | -0.85 |
| Tax Burden | 1.01 | 0.96 | 0.96 | 0.91 | 0.99 |
| Interest Burden | 1.17 | 1.02 | 1.09 | 1.04 | 1.01 |
| Research & Development to Revenue | 0.87 | 0.72 | 1.07 | 1.30 | 0.62 |
| SG&A to Revenue | 0.95 | 0.83 | 0.31 | 0.47 | 0.31 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.79 | -0.03 | 0.87 | 0.63 | 1.21 |
Currency in CNY
